Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature

Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus

(2010) Lawrence Blonde   AMERICAN JOURNAL OF MEDICINE

Acute or Chronic Upregulation of Mitochondrial Fatty Acid Oxidation Has No Net Effect on Whole-Body Energy Expenditure or Adiposity

(2010) Kyle L. Hoehn et al.   Cell Metabolism

Insulin Resistance in Nonalcoholic Fatty Liver Disease

(2010) E. Bugianesi et al.   CURRENT PHARMACEUTICAL DESIGN

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

(2010) R. A. DeFronzo   DIABETOLOGIA

Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6

(2010) Ken Shimamura et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes

(2010) Stuart A Morgan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

17β-Hydroxysteroid dehydrogenase inhibitors: a patent review

(2010) Donald Poirier   EXPERT OPINION ON THERAPEUTIC PATENTS

Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study

(2010) Riccardo C. Bonadonna et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

(2010) Elizabeth K. Hussey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake

(2010) D. P. Olson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438)

(2009) Serge Léger et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome

(2009) Bei B. Zhang et al.   Cell Metabolism

GPR40: Good Cop, Bad Cop?

(2009) T. Alquier et al.   DIABETES

Overexpression of GPR40 in Pancreatic  -Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic Mice

(2009) K. Nagasumi et al.   DIABETES

GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell

(2009) L. M. Lauffer et al.   DIABETES

The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis

(2009) B. Cariou   DIABETES & METABOLISM

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

(2009) Yoshikazu Fujimori et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007 – 2008

(2009) Jeffrey W Corbett   EXPERT OPINION ON THERAPEUTIC PATENTS

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

(2009) William N Washburn   EXPERT OPINION ON THERAPEUTIC PATENTS

Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes

(2009) Sandip B Bharate et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

GPR119 agonists for the treatment of type 2 diabetes

(2009) Robert M Jones et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia

(2009) Kara K. Osbak et al.   HUMAN MUTATION

11β-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation

(2009) Mark S. Cooper et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis

(2009) Hong Lan et al.   JOURNAL OF ENDOCRINOLOGY

Hepatic Fatty Acid Composition Differs between Chronic Hepatitis C Patients with and without Steatosis

(2009) Bianca M. Arendt et al.   JOURNAL OF NUTRITION

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Glucokinase and molecular aspects of liver glycogen metabolism

(2008) Loranne Agius   BIOCHEMICAL JOURNAL

The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice

(2008) Ruth Brownlie et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Glucose Sensing in L Cells: A Primary Cell Study

(2008) Frank Reimann et al.   Cell Metabolism

Selective Small-Molecule Agonists of G Protein-Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

(2008) C. P. Tan et al.   DIABETES

The Fatty Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat Feeding

(2008) M. Kebede et al.   DIABETES

Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver

(2008) A. Kotronen et al.   DIABETES

Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion

(2008) S. Edfalk et al.   DIABETES

Economic Costs of Diabetes in the U.S. in 2007

(2008)   DIABETES CARE

Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans

(2008) N. Stefan et al.   DIABETOLOGIA

Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells

(2008) H. E. Parker et al.   DIABETOLOGIA

A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release

(2008) Zhi-Liang Chu et al.   ENDOCRINOLOGY

11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity

(2008) Katherine A Hughes et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Glucokinase activators as new type 2 diabetes therapeutic agents

(2008) Ramakanth Sarabu et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119

(2008) Graeme Semple et al.   JOURNAL OF MEDICINAL CHEMISTRY

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

(2008) Y. Fujimori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family

(2008) B. Hagenbuch et al.   XENOBIOTICA

It's Not How Fat You Are, It's What You Do with It That Counts

(2008) Samuel Virtue et al.   PLOS BIOLOGY